Home | Sitemap | Search | ContactA- A A+
   
 
    Public Member Support us  
 

IBCSG 41-13 TREND 

A randomized phase II Trial evaluating the endocrine activity and efficacy of neoadjuvant degarelix versus triptorelin in premenopausal patients receiving letrozole for Primary endocrine responsive breast cancer

DESIGN

please click on the picture to see a larger version

Study Chair
Dr. Silvia Dellapasqua, Milan, Italy

Dr. Marco Colleoni, Milan, Italy

Statistician
Dr. P. Kathryn Gray

Lead Trial Coordinator
Holly Shaw

Data Managers
Karolyn Scott

Trial Monitors
Giuseppe Achille, Daniela Celotto, Carmen Comune
IBCSG Coordinating Center, Bern, Switzerland
Phone: +41 31 511 94 00
Fax: +41 31 511 94 01
Email: trend-monitoring@ibcsg.org

IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 833 3990
Email: ibcsg41_trend@fstrf.org

Date of Activation
March 28, 2013

Targeted Accrual
50 patients


News

14.06.2020:
Save the date and join the IBCSG Pink Ladies! June 14, 2020

20.03.2020:
The next IBCSG Annual Meeting will take place in Barcelona Spain on March 20 and 21, 2020.       

11.11.2019:
New publications are available 

All News

 
  Print